Last reviewed · How we verify
ELOCTA
At a glance
| Generic name | ELOCTA |
|---|---|
| Also known as | ELOCTATE, efmoroctocog alfa, rFVIIIFc, Eloctate, efmoroctocog alfa, rFVIIIFc |
| Sponsor | Swedish Orphan Biovitrum |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health
- Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products
- A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B
- rFVIIIFc (Elocta®) ITI Chart Review in Patients With Haemophilia A
- Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies (PHASE4)
- Study of Surgical Practices in Patients With Haemophilia A or B Treated With an Extended Half-life Recombinant Factor VIII-Fc or IX-Fc (ELOCTA®, ALPROLIX®)
- rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study (PHASE3)
- A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ELOCTA CI brief — competitive landscape report
- ELOCTA updates RSS · CI watch RSS
- Swedish Orphan Biovitrum portfolio CI